1. INTRODUCTION
Chemically, dapsone (4, 40 -diaminodiphenylsulfone, DDS) is an aniline
derivative, a drug of the sulfone class.1 Dapsone is
increasingly used in the treatment of a variety of dermatological
disorders such as acne, dermatitis herpetiformis, psoriasis, and
toxoplasma gondii infections and pneumocystis carinii pneumonia in
acquired immunodeficiency syndrome (AIDS) patients and is drug of choice
for leprosy commonly in combination with rifampicin and clofazimine in
Nepal.1-2 DHS is a severe idiosyncratic drug reaction
in response to dapsone characterised by the clinical symptoms of fever,
skin eruption, and internal organ involvement (lung, liver,
neurological, hematological and other systems) and DIH can be considered
as one of the spectrum of DHS.2 In general, prevalence
of DHS is 0.5-3%.2-4 Here we report a case who
presented with fatigue, jaundice and mild upper abdominal pain 3 weeks
after starting anti-leprosy drug regimen comprising dapsone.